AN2 Therapeutics, Inc. (ANTX) research
AN2 Therapeutics, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $5.61
- As of
Kresmion compiles this page from ANTX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
AN2 Therapeutics, Inc. (ANTX): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-11.
As of . Source: SEC EDGAR filings for ANTX. Method and limitations.
Share the ANTX intelligence card
See the full ANTX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ANTX on one page. Preview it with sample data, then open it live with a free account.
Preview the ANTX dossierActive signals for ANTX
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 34.6%, EPS $-0.18 vs $-0.2754 estimate
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +724% to ANTX (2026Q2)
- highINSTITUTIONAL_EXIT
TWO SIGMA INVESTMENTS, LP cut 91% of ANTX (2026Q2)
- mediumEARNINGS_MISS
Q1-2026: Missed consensus by 23.6%, EPS $-0.29 vs $-0.2346 estimate
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +2223% to ANTX (2026Q1)
FREE, NO ACCOUNT
Every signal on ANTX, as it fires
New filings, 13F moves and cross asset signals on ANTX land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ANTX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 037326105 · 2026Q2 | $11.2M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 037326105 · 2026Q2 | $4.6M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 037326105 · 2026Q2 | $628K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 037326105 · 2026Q2 | $77K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ANTX
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
ANTX against its peers
ANTX's return on equity of -66.3% ranks in the 31st percentile of 23 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | ANTX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 25.4M | n/a | 19 |
| Operating margin | n/a | -221.7% | n/a | 19 |
| Net margin | n/a | -202.2% | n/a | 19 |
| Return on equity | -66.3% | -37.6% | 31 | 23 |
Peers (24): PLX, CGEN, WHWK, NAGE, TRDA, RNAC, KROS, MGNX, ELDN, ALEC, LYEL, PRQR, SION, NAUT, LCTX, ACOG, XGN, SLGL, ZNTL, IVVD, BCYC, NGEN, ADAG, QTTB. Left out: VRXA (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (ANTX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow ANTX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ANTX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.